Recent advances in nanosized drug delivery systems for overcoming the barriers to anti-PD immunotherapy of cancer

Publication date: Available online 14 November 2019Source: Nano TodayAuthor(s): Xiaochen Liu, Dangge Wang, Pengcheng Zhang, Yaping LiAbstractCheckpoint blockade immunotherapy revolutionizes the field of cancer therapy, among which anti-programmed cell death (anti-PD) therapy is the most successful one in clinic. Despite the tremendous advancement, anti-PD therapy is still limited by barriers such as low response rate and immune related adverse effects (AEs), which are mainly resulted from poor intratumoral infiltration of cytotoxic T lymphocytes and off-tumor distribution of the anti-PD drugs. To address these issues, nanosized drug delivery systems (NDDS) have been fabricated to realize synergistic application with anti-PD drugs for anti-tumor immunity priming or enable targeting delivery of anti-PD drugs with versatile chemical properties. In this review, we summarize the major barriers for successful anti-PD therapy, highlight current advances in NDDS with improved anti-PD therapeutic benefits, and discussed the possible directions of the field.Graphical abstractCheckpoint blockade immunotherapy revolutionizes the field of cancer therapy in clinic. Various nanosized drug delivery systems (NDDS) have been fabricated to enhance the therapeutic benefits of anti-PD drugs or enable combined anti-PD therapies for more effective cancer immunotherapy. In this review, we summarize the major barriers for successful anti-PD therapy, highlight current advances in NDDS with improved an...
Source: Nano Today - Category: Nanotechnology Source Type: research

Related Links:

To investigate whether CD155 is an attractive target for T cell-mediated immunotherapy against human bladder cancer, we examined the novel bispecific antibody anti-CD3 x anti-CD155 (CD155Bi-Ab) for its ability to redirect activated T cells (ATCs) to target bladder cancer cells was examined. Expression of CD155 was detected by flow cytometry on the surface of bladder cancer cells, including T24 and Pumc-91 cells, and their chemotherapeutic drug-resistant counterparts. ATCs generated from healthy donors were stimulated with anti-CD3 monoclonal antibody, anti-CD28 monoclonal antibody and interleukin-2 (IL-2) for 14 days. The ...
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
Scientists at the National Cancer Institute'sSurgery Branch have developed a method to identify and generate T-cell receptor (TCR) engineered T- cells for personalized cancer therapy. The TCR is a complex of integral membrane proteins that recognizes antigens and activates T cells. Human cancers contain genetic mutations that are unique in each patient. The researchers found cancer-specific mutations by sequencing tumors and comparing with normal cells. Using tandem minigene constructs encoding all of the patient's tumor mutations, they first identified T cells that were reactive with the unique mutated antigens expressed ...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
(Yale University) In the last decade, scientists discovered that blocking a key regulator of the immune system helped unleash the body's natural defenses against several forms of cancer, opening up a new era of cancer immunotherapy. Now Yale scientists have essentially flipped this script and found that when impaired a molecularly similar regulator can cause the damaging immune system attacks on skin and organs that are the hallmark of the autoimmune disease lupus.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
AbstractCurrent therapeutic approaches in malignancy are often based on combination therapies, reflecting present understanding of the way different players act together in cancer. The cooperative activity of several elements can potentiate the pro-metastatic functions of the cancer cells and of the tumor microenvironment (TME), together leading to a more aggressive disease phenotype. The design of improved therapeutic modalities requires better identification of networks that act at specific cancer-related settings, and of the molecular mechanisms involved. Such studies will indicate if therapies that co-target several fa...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
PPARγ Agonists in Combination Cancer Therapies. Curr Cancer Drug Targets. 2019 Dec 08;: Authors: Mrowka P, Glodkowska-Mrowka E Abstract Peroxisome proliferator-activated receptor-gamma (PPARγ) is a nuclear receptor acting as a transcription factor involved in the regulation of energy metabolism, cell cycle, cell differentiation, and apoptosis. These unique properties constitute a strong therapeutic potential that place PPARγ agonists as one of the most interesting and widely studied anticancer molecules. Although PPARγ agonists exert significant, antiproliferative and tumoricid...
Source: Current Cancer Drug Targets - Category: Cancer & Oncology Authors: Tags: Curr Cancer Drug Targets Source Type: research
In this study, we generated two types of EGFR-specific CAR-modified T cells using lentiviral vectors with DNA sequences encoding the scFv regions of two anti-EGFR antibodies. The cytotoxic and antitumor effects of these CAR-modified T cells were examined in cytokine release and cytotoxicity assays in vitro and in tumor growth assays in TNBC cell line- and patient-derived xenograft mouse models. Both types of EGFR-specific CAR-T cells were activated by high-EGFR-expressing TNBC cells and specifically triggered TNBC cell lysis in vitro. Additionally, the CAR-T cells inhibited growth of cell-line- and patient-derived xenograf...
Source: Aging - Category: Biomedical Science Authors: Tags: Aging (Albany NY) Source Type: research
AbstractPro-inflammatory cytokines are crucial mediators of cancer development, representing potential targets for cancer therapy. The molecular mechanism of a vital pro-inflammatory cytokine, IL-17A, in cancer progression and its potential use in therapy through influencing fatty acid (FA) metabolism, especially FA uptake of cancer cells, remains unknown. In the present study, we used IL-17A and ovarian cancer (OvCa), a representative of both obesity-related and inflammation-related cancers, to explore the interactions among IL-17A, cancer cells and adipocytes (which can provide FAs). We found that in the presence of palm...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
Researchers from Case Western Reserve University have developed a new computational tool to predict, based on CT imaging, whether lung cancer patients will benefit from immune-checkpoint inhibitor cancer therapy. This is an exciting development for p...
Source: Medgadget - Category: Medical Devices Authors: Tags: Informatics Medicine Source Type: blogs
Abstract Nanoparticles in cancer therapy have garnered significant attention in the past few decades. Cancer immunotherapy, which is aptly called "the new-generation cancer therapy," is slowly making remarkable strides in the improvement of patient outcome and longevity. Taken together, nanoparticles in immune therapy have the potential to offer advantages of both nanoparticles and immune therapy on a single platform. PMID: 31776928 [PubMed - in process]
Source: Mol Biol Cell - Category: Molecular Biology Authors: Tags: Methods Mol Biol Source Type: research
The approval of two chimeric antigen receptor-modified T cell types by the US Food and Drug Administration (FDA) for the treatment of hematologic malignancies is a milestone in immunotherapy; however, the appl...
Source: Journal of Hematology and Oncology - Category: Hematology Authors: Tags: Review Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Chemistry | Immunotherapy | Nanotechnology